Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $37 to $38.
Stocks · News reference
Robinhood To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Wall Street analysts change outlook on top names. See all rating changes, including upgrades and downgrades, on analyst ratings page.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Morgan Stanley Maintains Equal-Weight on ACADIA Pharmaceuticals, Raises Price Target to $28
Morgan Stanley analyst Jeffrey Hung maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Equal-Weight and raises the price target from $27 to $28.
Citigroup Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40
Citigroup analyst Yigal Nochomovitz maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $39 to $40.
European Commission Approves Acadia’s DAYBU For Rett Syndrome Patients Aged Five And Older Following Successful Phase 3 LAVENDER Study
EAT Surges 69% in 3 Months: Is the Stock Still Attractive?
Brinker International (EAT) has surged 69.4% over three months as its Chili's brand demonstrates strong turnaround momentum with 6% comparable-sales growth, 1.5% traffic increases, and successful menu innovations like the Big Crispy Chicken Sandwich. The company projects fiscal 2027 EPS of $12.60-$13.40 supported by margin expansion, restaurant reimaging, and new-unit growth. Despite strong performance, EAT trades at a reasonable 17.32X forward P/E, below industry averages and comparable restaurant peers.
UBS Maintains Buy on Domino's Pizza, Raises Price Target to $385